AN INTELLIGENT APPROACH TO DRUG DISCOVERY

摘要

Aworld-first system developed by Fujifilm could significantly speed up and reduce the cost of creating leads for finding new pharmaceutical candidates. After two years of development, the technology, dubbed Artificial Intelligence-Amino Acid Mapping, or AI-AAM has finally made it possible to profile the way drug candidates bind to disease-associated receptors and find possible alternative molecules. It should be noted that AI-AAM only needs the structural formula of a known biologically active compound; it does not utilize any information of the 3D structure of a target protein. This is a major breakthrough in an industry where taking a drug from the lab to regulatory approval costs more than US$2.5 billion and takes at least 10 years.